Aspirin Reload Before Elective Percutaneous Coronary Intervention
Authors:
- Stefania BasiliStefania Basili
- Gaetano TanzilliGTGaetano Tanzilli
- Valeria RaparelliValeria Raparelli
- Camilla CalvieriCCCamilla Calvieri
- Pasquale PignatelliPPPasquale Pignatelli
- Roberto CarnevaleRoberto Carnevale
- Marcello DominiciMDMarcello Dominici
- Alessio FarcomeniAFAlessio Farcomeni
- Francesco BarillàFBFrancesco Barillà
- 1 August 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 7 (4) , 577-584
Abstract
Background—: Microvascular obstruction seems to predict poor outcome in patients undergoing elective percutaneous coronary intervention (PCI), but the underlying mechanism is still unclear. We analyzed whether serum thromboxane B 2 , a stable metabolite of thromboxane A 2 , may be implicated in post-PCI microvascular obstruction. Methods and Results—: We enrolled 91 patients (74 males, 66±10 years) on chronic low-dose aspirin therapy (aspirin, 100 mg daily) scheduled for elective PCI and randomly assigned to receive aspirin reload (325 mg orally, n=46) or no reload (control group, n=45) ≥1 hour before elective PCI. Serum levels of thromboxane B 2 , reperfusion indexes (corrected Thrombolysis In Myocardial Infarction frame count and myocardial blush grade), and serum cardiac troponin I were assessed before and after PCI. Serum thromboxane B 2 significantly increased after 120 minutes ( P =0.0447) from PCI in control but not in aspirin reload group. After PCI, both groups showed a statistically significant reduction in corrected Thrombolysis In Myocardial Infarction frame count more evident in aspirin reload group ( P =0.0023). Moreover, after PCI, 61% of patients allocated to aspirin reload and only 32% of patients allocated to control group reached normal microcirculatory reperfusion (myocardial blush grade=3); patients with myocardial blush grade=3 exhibited lower values of serum thromboxane B 2 compared with those with myocardial blush grade P =0.05). Periprocedural cardiac troponin I significantly increased (F=3.64; P =0.01334) and correlated with serum thromboxane B 2 (ρ=0.31; P =0.0413) in control but not in aspirin reload group. In addition, left ventricular ejection fraction significantly increased after PCI only in the aspirin reload group ( P =0.0005). Conclusions—: Aspirin loading dose before elective PCI improves myocardial reperfusion and injury indexes, suggesting a possible role of platelet thromboxane A 2 in microvascular occlusion. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01374698.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysisInternational Journal of Cardiology, 2013
- Anoxia-Reoxygenation Enhances Platelet Thromboxane A 2 Production via Reactive Oxygen Species–Generated NOX2Arteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Myocardial No-Reflow in HumansJACC, 2009
- Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary interventionEuropean Heart Journal, 2008
- Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush GradeCirculation, 2003
- No-Reflow PhenomenonCirculation, 2002
- Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous interventionJACC, 1999
- Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonistsThe American Journal of Cardiology, 1991
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988
- Aspirin, Sulfinpyrazone, or Both in Unstable AnginaNew England Journal of Medicine, 1985